Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the target of a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 7,902 shares, a growth of 395,000.0% from the May 31st total of 2 shares. Based on an average trading volume of 22,128 shares, the days-to-cover ratio is presently 0.4 days.
Oculis Price Performance
Oculis stock traded up $0.11 during mid-day trading on Thursday, reaching $4.22. The company had a trading volume of 852 shares, compared to its average volume of 6,217. Oculis has a 52 week low of $3.63 and a 52 week high of $22.64. The company has a 50 day moving average of $13.13 and a 200-day moving average of $13.56.
Oculis Company Profile
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Featured Articles
- Five stocks we like better than Oculis
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
